MX2020009580A - Proceso de preparacion de dos derivados de 4-{[(2s)-2-{4-[5-cloro- 2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}bu tanoil]amino}-2-fluorobenzamida. - Google Patents

Proceso de preparacion de dos derivados de 4-{[(2s)-2-{4-[5-cloro- 2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}bu tanoil]amino}-2-fluorobenzamida.

Info

Publication number
MX2020009580A
MX2020009580A MX2020009580A MX2020009580A MX2020009580A MX 2020009580 A MX2020009580 A MX 2020009580A MX 2020009580 A MX2020009580 A MX 2020009580A MX 2020009580 A MX2020009580 A MX 2020009580A MX 2020009580 A MX2020009580 A MX 2020009580A
Authority
MX
Mexico
Prior art keywords
chloro
oxopyridin
butanoyl
methoxy
phenyl
Prior art date
Application number
MX2020009580A
Other languages
English (en)
Inventor
Daniel Götz
Julian Egger
Michal Sowa
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2020009580A publication Critical patent/MX2020009580A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a un proceso para preparar 4-{[(2S)-2-{4-[5-cloro-2-(4-cloro-1H-1,2,3-triazol-1-il)fenil]-5- metoxi-2-oxopiridin-1(2H)-il}butanoil]amino}-2-fluorobenzamida (I) o 4-({(2S)-2-[4-{5-cloro-2-[4-(trifluorometil)-1H-1,2,3-triazo l-1-il]fenil}-5-metoxi-2-oxopiridin-1(2H)-il]butanoil}amino)-2-fl uorobenzamida (II) a partir de 2,5-dimetoxipiridina (III), 1-(2-bromo-4- clorofenil)-4-cloro-1H-1,2,3-triazol (X-Cl) o 1-(2-bromo-4-clorofenil)-4-(trifluorometil)-1H-1,2,3-triazol (X-CF3), 4-amino-2-fluorbenzamida (XIII) y ácido (2R)-2-aminobutanoico (XVII).
MX2020009580A 2018-03-15 2019-03-08 Proceso de preparacion de dos derivados de 4-{[(2s)-2-{4-[5-cloro- 2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}bu tanoil]amino}-2-fluorobenzamida. MX2020009580A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18161983 2018-03-15
PCT/EP2019/055815 WO2019175043A1 (en) 2018-03-15 2019-03-08 Preparative process of two 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide derivatives

Publications (1)

Publication Number Publication Date
MX2020009580A true MX2020009580A (es) 2020-10-05

Family

ID=61683650

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009580A MX2020009580A (es) 2018-03-15 2019-03-08 Proceso de preparacion de dos derivados de 4-{[(2s)-2-{4-[5-cloro- 2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}bu tanoil]amino}-2-fluorobenzamida.

Country Status (29)

Country Link
US (1) US11542245B2 (es)
EP (2) EP3889147A1 (es)
JP (1) JP7287978B2 (es)
KR (1) KR102807521B1 (es)
CN (1) CN111770917B (es)
AR (1) AR117400A1 (es)
AU (1) AU2019236369B2 (es)
BR (1) BR112020018562A2 (es)
CA (1) CA3093733A1 (es)
CL (1) CL2020002371A1 (es)
DK (1) DK3765452T3 (es)
ES (1) ES2920449T3 (es)
HR (1) HRP20220565T1 (es)
HU (1) HUE058796T2 (es)
IL (2) IL277240B2 (es)
JO (1) JOP20200232B1 (es)
LT (1) LT3765452T (es)
MX (1) MX2020009580A (es)
MY (1) MY201167A (es)
PE (1) PE20211395A1 (es)
PL (1) PL3765452T3 (es)
PT (1) PT3765452T (es)
RS (1) RS63338B1 (es)
SG (1) SG11202006710RA (es)
SI (1) SI3765452T1 (es)
TW (1) TWI823911B (es)
UA (1) UA126940C2 (es)
UY (1) UY38147A (es)
WO (1) WO2019175043A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140558A (ko) * 2020-02-11 2022-10-18 케미노바 에이/에스 (r)-2-아미노부탄산으로부터 s-베플루부타미드를 합성하는 방법
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
MX2023010614A (es) * 2021-03-09 2023-09-19 Bayer Ag Formas cristalinas de (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?, 5-dioxo-14-(trifluoro-metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2, 3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida.
EP4304561A1 (en) 2021-03-09 2024-01-17 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法
CN116262735B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262724B (zh) * 2022-11-18 2025-04-29 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262734B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 氧代吡啶类化合物及其制备方法和用途
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116082303B (zh) * 2022-12-21 2025-02-25 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其中间体和应用
WO2024251276A1 (zh) 2023-06-09 2024-12-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体和应用
CN116535392B (zh) * 2023-06-26 2023-09-05 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物的制备方法及中间体和应用
CN116621742B (zh) * 2023-06-09 2025-05-06 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116751136B (zh) * 2023-06-21 2025-08-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116621728B (zh) * 2023-06-09 2025-07-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116874387B (zh) * 2023-06-21 2025-08-26 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116730861A (zh) * 2023-06-21 2023-09-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN117164562B (zh) * 2023-09-07 2025-06-13 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117164561A (zh) * 2023-09-07 2023-12-05 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164565B (zh) * 2023-09-07 2025-05-27 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164564B (zh) * 2023-09-07 2025-07-08 成都施贝康生物医药科技有限公司 氧代哒嗪类化合物及其制备方法和用途
CN117164563B (zh) * 2023-09-07 2025-06-10 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN117164566B (zh) * 2023-09-07 2025-06-06 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117186073B (zh) * 2023-09-08 2025-06-06 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
CN107793396B (zh) * 2016-08-31 2021-02-26 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用
CA3123324A1 (en) * 2018-12-17 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
KR20210106504A (ko) * 2018-12-21 2021-08-30 바이엘 악티엔게젤샤프트 치환된 옥소피리딘 유도체
US20220144848A1 (en) * 2018-12-21 2022-05-12 Bayer Aktiengesellschaft Substituted oxopyridine derivatives

Also Published As

Publication number Publication date
TWI823911B (zh) 2023-12-01
HUE058796T2 (hu) 2022-09-28
JOP20200232A1 (ar) 2020-09-14
UY38147A (es) 2019-10-01
JP7287978B2 (ja) 2023-06-06
CA3093733A1 (en) 2019-09-19
DK3765452T3 (da) 2022-06-27
BR112020018562A2 (pt) 2020-12-29
CN111770917A (zh) 2020-10-13
SG11202006710RA (en) 2020-08-28
PT3765452T (pt) 2022-06-23
AU2019236369B2 (en) 2024-04-18
US20210017152A1 (en) 2021-01-21
WO2019175043A1 (en) 2019-09-19
EP3765452A1 (en) 2021-01-20
US11542245B2 (en) 2023-01-03
JOP20200232B1 (ar) 2023-09-17
PE20211395A1 (es) 2021-07-27
IL277240A (en) 2020-10-29
KR102807521B1 (ko) 2025-05-16
KR20200131241A (ko) 2020-11-23
AR117400A1 (es) 2021-08-04
UA126940C2 (uk) 2023-02-22
IL300463A (en) 2023-04-01
IL277240B2 (en) 2024-01-01
HRP20220565T1 (hr) 2022-06-10
TW202002969A (zh) 2020-01-16
PL3765452T3 (pl) 2022-08-01
RS63338B1 (sr) 2022-07-29
AU2019236369A1 (en) 2020-07-30
ES2920449T3 (es) 2022-08-04
SI3765452T1 (sl) 2022-06-30
IL277240B1 (en) 2023-09-01
RU2020133706A (ru) 2022-04-18
CN111770917B (zh) 2023-09-26
JP2021517573A (ja) 2021-07-26
MY201167A (en) 2024-02-08
LT3765452T (lt) 2022-05-25
EP3889147A1 (en) 2021-10-06
CL2020002371A1 (es) 2021-01-29
EP3765452B1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
MY201167A (en) Preparative process of two 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide derivatives
CA2388320A1 (en) N-substituted carbamoyloxyalkyl-azolium derivatives
ES2742077T3 (es) Inhibidores de autotaxina que comprenden un núcleo de anillo heteroaromático de bencil-amida cíclica
IT1256282B (it) Composizione farmaceutica che comprende una particolare forma fisica di un derivato di un'ammide eterociclica
HU211474A9 (en) Azole compounds, their production and use
BG63487B1 (bg) Използване на хетероциклени съединения
MY148078A (en) Novel piperazine salts as d3/d2 antagonists
NZ612119A (en) Use of sigma ligands in bone cancer pain
MX2024001442A (es) Derivados de pirazol microbiocidas.
CR20230162A (es) Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos
JOP20210227A1 (ar) شكل بلوري من مونوهيدرات 1-(1-أوكسو-1، 2-داي هيدروأيزوكينولين-5-يل)-5-(تراي فلوروميثيل)-n-(2-(تراي فلوروميثيل)بيريدين-4-يل)-1h-بيرازول-4-كربوكساميد
CN1137118C (zh) 用作广效性抗菌剂的水溶性唑类(一)
MX2025005222A (es) Derivados de pirazol microbiocidas
TH2001005199A (th) กระบวนการเตรียมของสองอนุพันธ์ 4-{[(2s)-2-{4-[5-คลอโร-2-(1h-1,2,3-ไตรอะซอล-1-อิล) ฟีนิล)-5-เมทอกซี-2-ออกโซไพริดิน-1(2h)-อิล}บิวทาโนอิล]อะมิโน}-2-ฟลูออโรเบนซาไมด์
NO961333L (no) Nye pyrazolderivater som angiotensin-II-antagonister
CA2217632A1 (en) Novel triazolones as apolipoprotein-b synthesis inhibitors
TW495508B (en) Amino acid ester containing azole antifungals
SE2151469A1 (en) Sortilin inhibitors
RU2022129311A (ru) Способ получения двух 4-{ [(2s)-2-{ 4-[5-хлор-2-(1h-1,2,3-триазол-1-ил)фенил]-5-метокси-2-оксопиридин-1(2h)-ил} бутаноил]амино} -2-фторбензамидных производных
NZ209707A (en) Sulphenamide derivatives and pharmaceutical compositions
ATE207481T1 (de) Kristallformen von 1-(5-methansulfonamidoindolyl- 2-carbonyl)-4-(3-(1-methylethylamino)-2- pyridinyl) piperazin
IL302677B1 (en) History of 1-(2-(4-cyclopropyl-1h-3,2,1-triazol-1-yl)acetyl)-4-hydroxypyrrolidine-2-carboxamide as VHL inhibitors for the treatment of anemia
ZA200207208B (en) Azole compounds as therapeutic agents for fungal infections.
JPS6345391B2 (es)
MXPA05013579A (es) Preparacion de 1,2,3-triazoles alquilados en n2.